ArticleOncotarget2016

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.

Giuseppe Bronte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.